Tecentriq – eBook Display Banners Conference – ASCO – 55169
Highlights from ASCO 2023 – HCC
ASCO HCC Annual 2023.indd
Read More
Liver Transplant Outcomes Worse for Black Patients With HCC
While liver transplantation was less likely for Black patients with HCC, those who did receive a...
Read More
Demographics Impact Time to Treatment Initiation for Patients With HCC
Hepatocellular carcinoma (HCC) comprises 75% of all liver cancer diagnoses in the United...
Read More
What Can Real-World Evidence Teach Us About Atezolizumab Plus Bevacizumab in HCC?
Therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients with...
Read More
IMbrave050: Adjuvant Atezolizumab Plus Bevacizumab Provides Landmark Recurrence-Free Survival for HCC
Adjuvant therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients...
Read More
Meeting Coverage: ASCO Voices
ASCO Voices continues to be one of the most compelling sessions offered at the ASCO Annual...
Read More
Ancillary Educational Events
Ancillary events are functions held adjacent to the ASCO Annual Meeting, including, but not...
Read More
Communities of Practice
Connect with colleagues that share your passion and goals through one of ASCO’s new Communities of...
Read More
Effects on Patient with HCC on Aspirin During In-Hospital Outcomes
Although new immunotherapies have been used, hepatocellular carcinoma (HCC) still presents a low...
Read More
Analyzing Adjuvant Atezo+Bev Vs. Active Surveillance in HCC Patients
In the IMbrave050 study, the combination of adjuvant atezo (atezolizumab) and bev (bevacizumab)...
Read More
Use of Atezolizumab and Bevacizumab to Treat Advanced HCC
In recent years, significant progress has been made in treating advanced unresectable...
Read More
Utilizing Genomic Features and Protein Markers for MRD Detection in HCC Patients
Many researchers determined that the clinical significance of circulating tumor DNA (ctDNA) in...
Read More
Impacting OS in Patients with Unresectable HCC with 1L TIS
Tislelizumab (TIS) is a specific monoclonal antibody targeting programmed cell death protein 1...
Read More